Advanced Dual-Hormone Therapy for Medical Weight Management
Tirzepatide represents a newer advancement in medical weight management. Unlike traditional GLP-1 medications, tirzepatide is a dual GIP and GLP-1 receptor agonist, targeting two complementary hormone pathways involved in appetite regulation, glucose metabolism, and energy balance.
First FDA-approved in 2022 for Type 2 diabetes, tirzepatide is the active ingredient in Mounjaro and Zepbound. Its dual-action mechanism stimulates glucose-dependent insulin secretion, helps regulate glucagon activity, improves blood sugar control, and acts on appetite pathways to increase satiety and reduce food intake.
Clinical trials have demonstrated substantial weight reduction with tirzepatide when combined with nutrition, physical activity, and appropriate medical supervision. Its dual-receptor activity provides an additional therapeutic approach to managing obesity and excess body weight.
At Sunkissed Med Spa, tirzepatide therapy begins with a comprehensive medical evaluation and individualized treatment plan. Through ongoing clinical monitoring and advanced body composition assessments, we evaluate fat loss, monitor changes in muscle mass, and make appropriate adjustments to support each patient’s progress.
Our approach combines advanced metabolic science with personalized medical care to support effective weight management and long-term health.